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Background: Reducing disease risk for women after menopause is global health issue. A major portion of the
Women’s Health Initiative (WHI) consisted of two clinical trials involving 161,809 post-menopausal women aged
50–79 that tested the effect of hormone replacement therapy (HRT) on reducing cardiovascular disease and
other secondary outcomes. Previous analyses of the data reveal that HRT should not be recommended for post-
menopausal women, but show potential benefits for younger women. Thus, there may be a critical period just
prior to or during the early stages of menopause where HRT could be both safe and beneficial.
Main body: Menopause marks the beginning of a process of non-reversible reduction in estrogen by which
estrogen levels decline progressively, followed by a reduction in estrogen receptors. This results in periods of
hormone-receptor imbalances, exacerbating the effects of lower serum estrogen and is considered the primarily
endocrinal source of menopause symptoms. Eventually a hormone-receptor balance is achieved at a lower level.
Here, we purport that the negative outcomes from WHI trials were primarily due to the fact preventive HRT was
initiated in women who had already achieved hormone-receptor equilibrium at lower hormonal levels.
Conclusion: We argue for further HRT clinical trials in women at varying stages of menopause, including pre-
menopause and early menopause, and in women from different countries. Variation across countries and
subgroups in how women experience menopause and perceive menopause symptoms suggest that biocultural
differences should be considered in both study design and measurement approaches to test the effectiveness
of HRT. Particularly, we recommend longitudinal studies to assess changes in hormonal level over time, and to
detect the “most effective period” for HRT to reduce health risk for women going through the whole menopause period.
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Reducing disease risk for women after menopause is
global health issue. A group of leading scientists from a
number of universities in the United States launched the
program Women’s Health Initiative (WHI) in 1991 with
funding primarily from the U.S. National Institutes of
Health. A major portion of WHI consists of two clinical
trials involving 161,809 post-menopausal women aged* Correspondence: jball2@ufl.edu
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(http://creativecommons.org/publicdomain/ze50–79 from 40 clinics. The two trials tested the effect of
hormone replacement therapy (HRT) on reducing cardio-
vascular disease (CVD), with invasive breast cancer (IBC),
hip fracture, stroke, and more as secondary outcomes
(e.g. [4, 9, 10]). The trials were halted due to observed
consistent increases in CVD and IBC risks [9].
More recently, Manson and colleagues performed an
age-stratified analysis of the WHI data, including add-
itional years of follow-up and concluded that, similar to
previous analyses, HRT should not be recommended for
chronic disease prevention in post-menopausal women
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aged 50–59), suggesting there may be a critical period just
prior to or during the early stages of menopause to initiate
preventive HRT. Similar critical period hypotheses have
been examined with respect to HRT and Alzheimer’s
disease (e.g. [6, 7]), and with HRT and cognition and
mood [2] with varying results.
These studies were conducted in post-menopausal
Caucasian women in the United States, rather than
women from multiple countries and ethnic backgrounds
that are in pre- and early-menopause. We argue that the
critical window theory should be further examined in
geographically and culturally diverse women cohorts who
in multiple stages of menopause and for other health
outcomes in a global setting before dismissing HRT as
dangerous in all postmenopausal women.
Menopause marks the beginning of a process of non-
reversible reduction in estrogen. According to the [1],
during the approximately one-year of menopausal transi-
tion, estrogen levels decline progressively, followed by a
reduction in estrogen receptors. This results in periods
of hormone-receptor imbalances, exacerbating the effects
of lower serum estrogen and is considered the primarily
endocrinal source of menopause symptoms. The subse-
quent alleviation of the menopause symptoms during
the early menopause period (3–4 years) indicates a
new, hormone-receptor equilibrium was reached at low
hormonal levels, which is associated with an increased
risk of CVD. The rationale of the WHI trials was to
supply estrogen with an expectation to curb this risk of
CVD [3].
The negative outcomes from WHI trials were primarily
due to the fact preventive HRT was initiated in women
who had already achieved hormone-receptor equilibrium
at lower hormonal levels [5]. Hormonal therapy at this
period will disturb the established balance. Endocrino-
logically, it would be more favorable if hormone therapy
were to be initiated during the premenopausal transition
period when the new hormone-receptor equilibrium at
the low hormonal levels has not yet been established [1].
Appropriate levels of estrogen supplementation during
this period would minimize periods of hormone-receptor
imbalance and would thus allow women to proceed
through the menopausal transition at a slower pace, less-
ening menopause symptoms and reducing other health
risks, including cardiovascular disease [3].
Conclusions
Furthermore, globally, women’s hormonal levels and the
changes in those levels during menopause can vary widely
between countries. Similarly, how women experience
menopause and perceive menopause symptoms suggest
that biocultural differences should be considered when
selecting both study design and measurement approachesto test the effectiveness of HRT [8]. Particularly, we rec-
ommend longitudinal studies to assess changes in hormo-
nal level over time, and to detect the “most effective
period” for HRT to reduce health risk for women going
through the whole menopause period.
There is significant need for additional longitudinal
studies like the WHI in multiple international contexts
to test this hypothesis by recruiting and following
women in different countries based on their stage of
menopause, and to tease out confounding from life-
style, cultural and genetic variation. Through these
studies, we could devise appropriate HRT dosage and
timing recommendations based on existing knowledge
of hormone and receptor decline following menopause
using a time-since-menopause analysis [3], and design
the trials to address the variable health concerns of the
multiple populations that are represented. While it
might be technically and practically challenging to
identify and recruit women in menopausal transition
stage for research purpose, the criterion for menopause
transition established by [1] provide a solid foundation
for developing valid measurement tools to address this
challenge. Appropriately timed HRT has the potential
to not only alleviate menopause symptoms, but also to
reduce risk of CVD, IBC and other negative health out-
comes across the globe.
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